Anxiety, dizziness, headache, insomnia, memory impairment
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age: 18–65 years7) All participants consented to participation and signed an informed consent form; 2.Study subjects were patients with anxiety disorders or comorbid anxiety conditions induced by stress or psychological trauma; 3.Patients must be capable of independent decision-making, have no communication barriers, and be right-handed; 4.Patients with severe cardiovascular or cerebrovascular diseases were excluded; 5.Participants were screened using the GAD-7, PHQ-9, and VAS scales; only those with moderate to severe anxiety or comorbid anxiety conditions were enrolled; 6.All participants consented to participation and signed an informed consent form; 7.Participants were randomly assigned via digital randomization to either the treatment group (low-frequency combined transcranial magnetic stimulation + pharmacotherapy) or the control group (standard pharmacotherapy);
Exclusion criteria
Exclusion criteria: 1.Patients under 18 years of age, or 65 years older; 2.Patients with severe organic cardiac or cerebral diseases (those with severe arrhythmias, severe epilepsy, or unsatisfactory treatment responses); 3.Patients with severe mental disorders such as schizophrenia; 4.Patients with metallic foreign bodies in the body, including coronary stents or intracranial metal stents; 5.Patients without legal capacity or those with severe cognitive impairment; 6.Patients who refuse participation in the study; 7.Vulnerable populations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GAD7;Hamilton Anxiety Scale score;VAS score;Efficacy assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocyte subsets or LP-PLA2, etc.; | — |
Countries
China
Contacts
Baotou Central Hospital